Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to -$778000.0.

  • Denali Therapeutics' Cash from Financing Activities rose 9580.8% to -$778000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year decrease of 10143.66%. This contributed to the annual value of $484.3 million for FY2024, which is 261775.53% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Cash from Financing Activities is -$778000.0, which was up 9580.8% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Cash from Financing Activities ranged from a high of $500.3 million in Q1 2024 and a low of -$18.6 million during Q3 2024
  • For the 5-year period, Denali Therapeutics' Cash from Financing Activities averaged around $43.6 million, with its median value being $3.8 million (2021).
  • Over the last 5 years, Denali Therapeutics' Cash from Financing Activities had its largest YoY gain of 3108921.45% in 2024, and its largest YoY loss of 84474.32% in 2024.
  • Over the past 5 years, Denali Therapeutics' Cash from Financing Activities (Quarter) stood at $5.2 million in 2021, then skyrocketed by 5698.2% to $299.7 million in 2022, then plummeted by 98.43% to $4.7 million in 2023, then plummeted by 188.59% to -$4.2 million in 2024, then surged by 81.33% to -$778000.0 in 2025.
  • Its last three reported values are -$778000.0 in Q3 2025, $1.6 million for Q2 2025, and -$3.8 million during Q1 2025.